Veracuity Blog A New Approach at Conducting Post-Market Drug Safety Surveillance The early foundation of Veracuity’s platform eVERA tracks back to a series of works by Dr Veronika Valdova in collaboration with Dr Jonathan Fishbein. The works describe the shortcomings of the current post-market drug safety surveillance and outline ways the process can be optimized.…
DetailsVeracuity Blog The opioid epidemic in drug safety reporting systems Last week, the founder of Insys Therapeutics, John Kapoor (76), was sentenced to 66 months in prison for orchestrating a scheme to bribe physicians to prescribe Subsys, a highly addictive form of fentanyl, to patients who did not need this drug. Five corporate executives, including…
DetailsVeracuity Blog The impact of data breaches in healthcare on research In the U.S., summary details of private health information breaches that involved more than 500 individuals are available at the HHS OCR portal called Wall of Shame for the public to view [1]. In Europe, EU-level legislation on data privacy has to be transposed…
DetailsVeracuity Blog Balancing patient privacy and research in care delivery Balancing patient privacy and research in care delivery, including the use of electronic health records (EHRs) for screening and research, is an ongoing challenge. Registries that contain information that is sensitive and confidential represent a unique set of challenges that impact patient populations enrolled in…
Details